Aventis Alvesco For Asthma Is One Of Five NDA/BLA Filings Planned For 2003
Executive Summary
Aventis is planning a third quarter NDA filing for the asthma therapy Alvesco, one of up to five novel agents the company expects to reach the filing stage by early 2004
You may also be interested in...
Aventis Plans To Launch Genasense, Ketek and Apidra In 2004
The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco
Aventis Plans To Launch Genasense, Ketek and Apidra In 2004
The launch of Genasense will be a key step in Aventis' plans to build its oncology franchise, Chief Operating Officer Richard Markham said Jan. 13 during the J.P. Morgan health care conference in San Francisco
Aventis abandons cariporide
Aventis will not seek regulatory approval for cariporide, company says May 16. Phase III trial for cardiovascular drug candidate was halted in July 2002 by data safety monitoring board (1"The Pink Sheet" Feb. 24, p. 24)...